Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX's door with an IPO application
A month after the Hong Kong Stock Exchange opened its doors to pre-revenue biotechs — and received one guest, Ascletis — Hua Medicine has walked in with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.